FOLH1 and thyroid cancer: Our study showed that an absorbed dose prediction based on a single time point [68Ga]Ga-PSMA-PET scan is feasible, similar to what earlier studies found for 124I-PET/CT dose prediction of 131I-therapy in thyroid cancer patients [35–40].